Can AI Cure Cancer? It Already Is.

An AI cure for cancer is closer than most people think. There is no single diagnostic or treatment algorithm that can eliminate the disease overnight. But what is happening in cancer medicine today is paving the way toward that reality. AI is steadily removing guesswork from how cancer is detected, classified, and treated. This kind of progress may not always make headlines, but in oncology, removing guesswork saves lives.

One of the clearest leaders in this shift is Tempus, a MedTech innovator that treats cancer not as a single disease, but as a prediction problem. By modeling cancer using data at a scale no human clinician could manage alone, Tempus is helping transform clinical intuition into measurable, actionable insight.

Tempus has pushed the field forward with AI-driven predictive diagnostics, including its Immune Profile Score (IPS), a multimodal biomarker designed to predict patient response to immune checkpoint inhibitors. By integrating large-scale genomic, clinical, and molecular datasets, IPS outperforms traditional biomarkers such as PD-L1, MSI, or tumor mutational burden, enabling clinicians to select more effective therapies earlier in the care pathway.

Its selection by ARPA-H for the ADAPT program signals that these models are moving beyond theory into real-world therapeutic development, supporting national efforts to accelerate precision cancer care. At the same time, Tempus is scaling its impact through major clinical collaborations. Partnerships with Northwestern Medicine and NYU Langone Health are expanding access to AI-enabled genomic testing and embedding multimodal analytics directly into clinical research workflows, accelerating biomarker discovery across diverse patient populations.

All of this is supported by continued investment in infrastructure, including generative AI enhancements to Tempus One. These capabilities allow clinicians and researchers to query millions of structured and unstructured patient records with unprecedented speed and clarity. They are not incremental upgrades, but a shift in how cancer data is explored and applied, giving medical teams a meaningful advantage in translating insight into action at a pace that matters in the race for a cure.

While Tempus is advancing patient care through analytics, it is also shaping the path forward for emerging innovators. As AI-enabled oncology software becomes more established, the FDA has begun issuing new 510(k) product codes and refining existing classifications for diagnostic SaMD. For founders, this evolution brings clearer regulatory expectations, easier predicate selection, and more predictable paths to market. Innovation in cancer diagnostics is not only improving care. It is lowering the barrier for the next generation of companies to reach patients at scale.

If you’re building the future of diagnostics and want a clear path to market, contact us. We help teams translate breakthrough AI into FDA-ready products that reach patients faster.